Background
==========

Alterations in cell proliferation and tissue remodeling are major hallmarks of cancer. Given that these two physiological processes require a significant investment of metabolic resources, we hypothesize that the metabolism of cancer cells is, in a first approximation, determined by the magnitude of cell proliferation and tissue remodeling.

Materials and methods
=====================

To address this question in further detail we have analyzed *in vitro* data characterizing cancer cell lines and gene expression profiles of human cancers.

Results
=======

We show that the metabolism of cancer cells is strongly correlated with cell proliferation and tissue remodeling. Based on *in vitro* data, cancer cell lines align from an extreme of highly proliferating cells of relatively small size to another extreme of slowly proliferating cells with large size and mesenchymal properties \[[@B1]\]. Similarly, in human cancers we detect a strong negative correlation between gene signatures associated with cell proliferation and tissue remodeling \[[@B2]\]. The stratification of human cancers based on the cell-proliferation/ tissue-remodeling signatures results in divergence in the survival plots as significant as those obtained using current site-specific classifications. Furthermore, *in vitro* data suggest that these different subtypes have a differential sensitivity to diverse drug classes targeting metabolism \[[@B1]\].

Conclusions
===========

We conclude that human cancers can be subject to a universal cell-proliferation/tissue-remodeling classification independent of their site of origin that can guide personalized treatment targeting cancer metabolism.
